ZL-1218 

ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

ZL-1218 depletes approximately 50% of Treg cells in mouse dissociated tumor cells (DTCs)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ZL-1218 reduces intratumoral Treg cells and inhibits tumor growth in a dose-dependent manner in syngeneic tumor models, while increasing the CD8⁺ T/Treg ratio without depleting peripheral Tregs in human CCR8 knock-in mouse models bearing syngeneic tumors^[1][2].
ZL-1218 (100 mg/kg, i.v., 5 weeks) demonstrates no safety concerns in non-human primates^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1237  [NCBI]

P51685

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jing Zhang, et al. Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells. Cancer Res (2022) 82 (12_Supplement): 3590.

  [2]. Jing Zhang, et al. 1399 ZL 1218 targets the most suppressive intratumoral Treg subpopulation to avoid peripheral toxicities. Journal for Immuno Therapy of Cancer. 7 November 2022 Volume 10,Issue Suppl

  [3]. Elena Garralda;et al. Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor. Cancer Res (2024) 84 (7_Supplement): CT162.